Evidence map›Paper›PMID 39543163›Full record

ArticleScientific reports2024

Proteomic profile of the antibody diversity in circulating extracellular vesicles of lung adenocarcinoma.

Xinfu Huang, Lijuan Xiong, Yang Zhang, Xin Peng, Hongping Ba, Peng Yang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinfu Huang *The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Lijuan Xiong *The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Yang ZhangThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Xin PengThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Hongping BaDepartment of Quality Evaluation, Wuhan Center for Clinical Laboratory, No. 24, Jianghan North Road, Jiang'an District, Wuhan, 430400, China. bhpsky@163.com.
Peng YangThe Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China. 1874660968@qq.com.

Funding

Guizhou Provincial Science and Technology Projects [2020]4Y178Science and Technology planning Foundation of Guiyang [2020]-16-18Scientific research project of the Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine GZEYK[2020]26Technology Fund of the Guizhou Provincial Health Committee gzwkg2019-1-198The funding for Scientific Research Projects from Wuhan Municipal Health Commission WX23A37
6 · The paper itself

Abstract

Immunoglobulin diversity encompasses B-cell receptor, T-cell receptor, and antibody diversity. Existing studies have focused more on the role of B-cell and T-cell receptor diversity in tumor immunity, while the role of antibody diversity is less understood. This study examined and compared the blood extracellular vesicles (EVs) of lung cancer patients and healthy individuals using proteomics and bioinformatics analyses. The results revealed that among the 270 identified proteins, those involved in defense mechanisms were the most abundant. Most of these were antibody subtypes, accounting for 50.00%. Similarly, of the 40 identified EVs differentially expressed proteins (DEPs), 29 were involved in defense mechanisms (72.50%), with a higher proportion being antibody subtypes (82.76%). Furthermore, 24 DEP antibody subtypes were implicated in 18 immune reaction-related signaling pathways. These findings suggest that human serum EVs contain a significant number of antibody subtypes, and the antibody subtypes from lung cancer serum EVs differ from those of healthy controls (HCs). The variations in antibody diversity may be closely associated with lung cancer tumor immunity.

Indexed as

Adenocarcinoma of LungExtracellular VesiclesLung NeoplasmsProteomicsAgedCase-Control StudiesComputational BiologyFemaleHumansMaleMiddle AgedProteomeProteomeAntibody diversityLung adenocarcinomaPlasma extracellular vesiclesProteomicsTumor immune

Identifiers

PMID39543163
PMCPMC11564652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.